Fortress Biotech (FBIO) Common Equity (2010 - 2026)

Fortress Biotech's Common Equity history runs 16 years deep, the most recent figure standing at $62.2 million for Q4 2025.

• In Q4 2025, Common Equity rose 173.49% year-over-year to $62.2 million; the TTM figure through Dec 2025 stood at $62.2 million (up 173.49% YoY), while the FY2025 annual figure was $62.2 million, up 173.49% from the prior year.
• Common Equity for Q4 2025 stood at $62.2 million, up from $55.9 million in the prior quarter.
• The five-year high for Common Equity was $248.3 million in Q2 2021, with the low at -$15.9 million in Q2 2023.
• The 5-year median for Common Equity is $43.7 million (2022), against an average of $79.8 million.
• Peak annual rise in Common Equity reached 1332.7% in 2024, while the deepest fall reached 119.88% in 2024.
• Fortress Biotech's Common Equity stood at $225.9 million in 2021, then tumbled by 77.85% to $50.0 million in 2022, then sank by 96.83% to $1.6 million in 2023, then soared by 1332.7% to $22.7 million in 2024, then surged by 173.49% to $62.2 million in 2025.
• Business Quant data shows FBIO's Common Equity at $62.2 million in Q4 2025, $55.9 million in Q3 2025, and $37.4 million in Q2 2025.